Coote Group

Group Highlights

Research is focused on identifying new treatments for Multi-Drug Resistant (MDR) human pathogens.
Novel treatments can be single therapies or combinations. Combinations can be derived from antibiotics; antibiotic resistance ‘breakers’ eg. Beta-lactamase inhibitors; efflux-pump inhibitors; or repurposed drugs.
Principal organisms tested are Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, Staphylococcus aureus, Fast-growing Mycobacteria and Candida albicans.
In addition to traditional in vitro microbiology techniques eg. MIC, checkerboard and time-kill assays we use an in vivo invertebrate infection model to test for efficacy of novel treatments versus real infections. This model employs the larvae of the Greater Wax moth (Galleria mellonella).

Recent papers

Carbapenem-only combination therapy against multi-drug resistant Pseudomonas aeruginosa: assessment of in vitro and in vivo efficacy and mode of action
Mackay, B., Parcell, B. J., Shirran, S. L. & Coote, P. J., 25 Oct 2022, In: Antibiotics. 11, 11, 19 p., 1467.

Repurposing the anti-viral drug zidovudine (AZT) in combination with meropenem as an effective treatment for infections with multi-drug resistant, carbapenemase-producing strains of Klebsiella pneumoniae
DeSarno, A. E., Parcell, B. J. & Coote, P. J., 14 Oct 2020, (E-pub ahead of print) In: Pathogens and Disease. Advance Article

Dual β-lactam combination therapy for multi-drug resistant Pseudomonas aeruginosa infection: enhanced efficacy in vivo and comparison with monotherapies of penicillin-binding protein inhibition
Siriyong, T., Murray, R. M., Bidgood, L. E., Young, S. A., Wright, F., Parcell, B. J., Voravuthikunchai, S. P. & Coote, P. J., 24 Jun 2019, In: Scientific Reports. 9, 13 p., 9098.